Shattuck Labs, Inc. STTK SL-325 — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Shattuck Labs, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Shattuck Labs, Inc.'s sl-325 — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Shattuck Labs, Inc.'s SL-325 — R&D?
- Shattuck Labs, Inc. (STTK) reported SL-325 — R&D of $2.86M in Q1 2026.
- How has Shattuck Labs, Inc.'s SL-325 — R&D changed year-over-year?
- Shattuck Labs, Inc.'s SL-325 — R&D increased by 28.4% year-over-year, from $2.23M to $2.86M.
- What does SL-325 — R&D mean?
- This metric represents the direct operating expenses allocated to the research, clinical development, and preclinical testing of the SL-325 product candidate. It captures the investment required to advance this specific therapeutic asset through the drug development pipeline, including costs for clinical trials, manufacturing process development, and regulatory activities. Monitoring this spend provides insight into the company's capital allocation strategy and the pace of development for this particular pipeline asset.